Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Rating of “Moderate Buy” by Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $20.00.

NBTX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. TD Cowen started coverage on Nanobiotix in a research note on Friday, February 6th. They set a “buy” rating on the stock. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Stock Up 1.5%

NASDAQ:NBTX opened at $24.49 on Friday. Nanobiotix has a 52 week low of $2.95 and a 52 week high of $30.35. The firm’s 50-day simple moving average is $21.93 and its 200 day simple moving average is $17.83.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.